Prudential Financial

SAN FRANCISCO--(BUSINESS WIRE)--Affirm (NASDAQ: AFRM), the payment network that empowers consumers and helps merchants drive growth, and PGIM Fixed Income, a Prudential Financial (NYSE: PRU) company and one of the largest global fixed income managers with $862 billion in assets under management1, today announced the expansion of their capital partnership with a new revolving pass-through loan sale facility that will invest up to $3 billion over 36 months by purchasing up to $500 million of Affi.» Mehr auf businesswire.com

Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,461 shares of the company’s stock, valued at approximately $59,000. A number of other large investors also recently bought and sold shares of the stock. SG Americas Securities LLC raised its stake in TScan Therapeutics by 31.2% during the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after purchasing an additional 4,852 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after acquiring an additional 5,694 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after acquiring an additional 6,550 shares in the last quarter. Barclays PLC lifted its holdings in shares of TScan Therapeutics by 16.3% during the 4th quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after acquiring an additional 9,441 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics during the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 82.83% of the company’s stock. TScan Therapeutics Price Performance TCRX opened at $1.69 on Wednesday. The company has a 50-day moving average of $1.43 and a 200-day moving average of $2.18. The company has a market capitalization of $95.64 million, a P/E ratio of -1.59 and a beta of 0.98. TScan Therapeutics, Inc. has a 1-year low of $1.02 and a 1-year high of $9.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million. Equities analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year. Analysts Set New Price Targets TCRX has been the topic of several recent research reports. HC Wainwright reduced their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th. Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays reduced their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $7.80. View Our Latest Research Report on TCRX Insider Activity at TScan Therapeutics In other news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of TScan Therapeutics stock in a transaction on Tuesday, May 20th. The stock was purchased at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the purchase, the insider now directly owns 7,946,141 shares of the company’s stock, valued at approximately $9,535,369.20. This trade represents a 17.79% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.35% of the company’s stock. TScan Therapeutics Profile (Free Report) TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.» Mehr auf defenseworld.net

Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.» Mehr auf seekingalpha.com